Search Results
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
various titration schemes, pharmacokinetics (PK) and preliminary efficacy of ASC30 once-daily oral tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2). ASC30 once-daily oral tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 18:01 ET Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
demonstrate that orforglipron (6 mg, 12 mg, 36 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body
More news about: Eli Lilly and Company
Sep 16, 2025, 08:37 ET Music Takes the Stage at CREATE 2025: Custom Channels Named Official Music Sponsor
BMI, the 80-year-old music licensing agency that protects the interests of recording artists and that Custom Channels supports through artist royalty payments. Dan Spears, Vice President of Industry Relations at BMI, commented on the role
More news about: Custom Channels